FLG and primary cutaneous T-cell non-Hodgkin lymphoma: Tofacitinib, a pan-JAK inhibitor, showed promise in enhancing skin barrier integrity in CTCL patients by up-regulating barrier proteins like filaggrin, which may provide dual benefits by targeting both the malignant T cells and alleviating skin-related symptoms in CTCL [42].